Related Experiment Videos
5-hydroxytryptamine and platelet aggregation. Summary This summary is machine-generated. 5-Hydroxytryptamine (5-HT) primarily causes shape change and reversible aggregation in human platelets. However, 5-HT amplifies other agonist-induced aggregations and induces strong aggregation in presensitized platelets, suggesting a role in hemostasis.
You might also read
Related Articles Articles linked to this work by shared authors, journal, and citation graph.
All12 Same author6 Same journal6
Area of Science:
Biochemistry Hematology Pharmacology Background:
5-Hydroxytryptamine (5-HT), also known as serotonin, is a monoamine neurotransmitter. Platelets play a crucial role in hemostasis and thrombosis. Purpose of the Study:
To investigate the effects of 5-HT on human platelet activation. To elucidate the mechanisms and receptors involved in 5-HT-mediated platelet responses. Main Methods:
Platelet aggregation assays with various agonists. Receptor-binding studies. Pharmacological characterization of 5-HT receptors on platelets. Main Results:
Human platelets exhibit shape change and reversible aggregation in response to 5-HT.
Related Experiment Videos
5-HT potentiates aggregation induced by ADP, collagen, epinephrine, and norepinephrine.
5-HT induces strong aggregation in platelets pre-sensitized with norepinephrine, lysolecithin, or Thrombofax.
Functional receptors, potentially 5-HT2 (S2) type, mediate these effects, distinct from uptake receptors.
Prolonged 5-HT exposure leads to transient tachyphylaxis. Conclusions:
5-HT acts as a modulator of human platelet activity. The findings suggest a role for 5-HT in secondary platelet aggregation, hemostasis, and thrombus formation. Specific 5-HT receptors are involved in platelet modulation.